Merck, a leading science and technology company, has announced the completion of its acquisition of Mirus Bio for approximately US$ 600 million (€ 550 million), following regulatory clearances and the fulfillment of other customary closing conditions. This acquisition is a strategic move to enhance Merck’s capabilities in viral vector manufacturing and demonstrates the company’s commitment to supporting cell and gene therapy advancements from preclinical stages through to commercial production. Merck acquired Mirus Bio from Gamma Biosciences, a life sciences platform established by global investment firm KKR.
“Novel modalities like cell and gene therapies have immense potential for bringing new curative treatments to patients,” said Sebastian Arana, Head of Process Solutions, Life Science business of Merck. “Mirus Bio’s advanced technology, coupled with our bioprocessing expertise and broad portfolio, will enable us to deliver integrated solutions across the viral vector value chain and meet the growing demand for these life-saving therapies.”
Mirus Bio specializes in developing and commercializing transfection reagents, such as TransIT-VirusGEN®. These reagents are crucial for producing viral vector-based gene therapies. The acquisition strengthens Merck’s upstream portfolio and allows for an integrated viral vector manufacturing offering.
With Mirus Bio’s advanced transfection technologies, Merck’s Life Science business sector is further reinforced. Merck provides solutions for every step of the viral vector manufacturing process, advancing cell and gene therapies from preclinical through commercial production. The company’s extensive portfolio includes cell lines, cell culture media, process materials like chemicals, buffers, and enzymes, as well as systems, filters, hardware, and consumables. Merck’s expertise spans various viral vector types, including adeno-associated virus, lentivirus, and adenovirus. Additionally, Merck offers contract testing and comprehensive CDMO services for viral vector manufacturing, leveraging three decades of experience in supporting cell and gene therapies.
